Search

Displaying results 4091 - 4100 of 10000 in total
  1. Drug

    AZD3409

    go.drugbank.com/drugs/DB04893
    Experimental

    As of February 2007 the development of AZD3409 had been discontinued. … AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004.

    Categories: Heterocyclic Compounds, 1-Ring
  2. Target

    Proto-oncogene tyrosine-protein kinase ROS

    go.drugbank.com/bio_entities/BE0009534
    TargetHumans

    Receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. NELL2 is an endogenous ligand for ROS1.

    Synonyms: c-Ros receptor tyrosine kinase, Receptor tyrosine kinase c-ros oncogene 1
  3. Drug

    SC-236

    go.drugbank.com/drugs/DB14059
    Experimental

    SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) [L2964] that has been studied in cancer therapy [A33375], lower back pain [A33376], and inflammation [A33373], [A33374

    Categories: Heterocyclic Compounds, 1-Ring
  4. Drug

    AVXS-301

    go.drugbank.com/drugs/DB17943
    Experimental

    AVXS-301 consists of an adeno-associated virus serotype 9 (AAV9) designed to express the superoxide dismutase 1 (SOD1) gene.

  5. Drug

    SJG-136

    go.drugbank.com/drugs/DB11965
    Investigational

    SJG-136 has been used in trials studying the treatment of Recurrent Fallopian Tube Cancer, Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and

    Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-Ring
  6. Drug

    PF-05175157

    go.drugbank.com/drugs/DB12096
    Investigational

    PF-05175157 has been used in trials studying the basic science and treatment of Acne Vulgaris, Diabetes Mellitus, Type 2 Diabetes Mellitus, Diabetes Mellitus Type 2, and Diabetes Mellitus, Type 2, among

  7. Drug

    Dutasteride

    go.drugbank.com/drugs/DB01126
    ApprovedInvestigational

    [A1909] Type I and II 5α-reductase enzymes convert testosterone into dihydrotestosterone (DHT), a primary hormonal mediator that plays a role in the development and enlargement of the prostate gland. … It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner.

    Mixtures: HIPERDEXT®, TASTILOZ ®Categories: 5-alpha Reductase Inhibitors, Cytochrome P-450 Substrates
  8. Target

    Calpain-1 catalytic subunit

    go.drugbank.com/bio_entities/BE0003346
    TargetHumans

    Calcium-regulated non-lysosomal thiol-protease which catalyzes limited proteolysis of substrates involved in cytoskeletal remodeling and signal transduction (PubMed:19617626, PubMed:21531719, PubMed:2400579). Proteolytically cleaves CTBP...

    Synonyms: Cell proliferation-inducing gene 30 protein
  9. Drug

    105AD7

    go.drugbank.com/drugs/DB05113
    Investigational

    metastatic colorectal cancer patients. 105AD7 may be a suitable vaccine for treatment of this disease. … 105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in

  10. Drug

    SR-9011

    go.drugbank.com/drugs/DB14014
    Experimental

    SR-9011 is a REV-ERB agonist. … SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues

    Categories: Heterocyclic Compounds, 1-RingSynonyms: 1-Pyrrolidinecarboxamide, 3-((((4-chlorophenyl)methyl)((5-nitro-2-thienyl)methyl)amino)methyl)-n-pentyl-